Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Name: Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
Published: 2016
License: Public Domain

National Cancer Institute, Naples · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

liquid-biopsy

non-squamous non-small cell lung cancer, stage iv, stage iiib, egfr mutation, non-squamous, liquid biopsy, erlotinib, bevacizumab, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Related documents